Bioinformatics Identification of Green Tea Anticancer Properties: a Network-Based Approach

Document Type : Original paper

Authors

1 Proteomics Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

2 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

3 Traditional Medicine and Materia Medica Research Center and Department of Traditional Pharmacy, School of Traditional Medicine, Shahid Beheshti University of medical Sciences, Tehran, Iran.

4 Department of Surgery, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.

Abstract

Background and objectives: Promising anticancer properties are associated with the consumption of green tea. On the other hand, lung cancer has been showing to possess the highest number of death compared to other types of cancer. The aim of this study was to understand the mechanisms by which green tea shows this effect; bioinformatics study of proteome profile could be essential. For this reason, the proteomics analysis of human lung adenocarcinoma A-549 cells treated with green tea extract was chosen for protein-protein interaction (PPI) network analysis. Methods: Cytoscape v.3.8.2 and its applications analyzed a number of 14 differentially expressed proteins (DEPs) from green tea treatment experiment as two networks. The biological annotations and action type exploration of the hub-bottlenecks of the PPI network were then carried out. Results. The investigation indicated that among 14 queries DEPs, HNRNPA2B1, PCBP1, and HNRNPC may show substantial role. Moreover, HSPA8 was the top hub-bottleneck and half of the central protein groups were enriched with heterogeneous nuclear ribonucleoproteins complex family (HNRNPs). Conclusion. The anticancer bioinformatics study of green tea suggests a complex nature for green tea. This finding urges complementary evaluations to validate whether green tea is applicable as an anticancer agent in medicine.

Keywords

Main Subjects


[1] Singh K, Bhori M, Kasu YA, Bhat G, Marar T. Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity–exploring the armoury of obscurity. Saudi Pharm J. 2018; 26(2): 177–190.
[2] ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium. Pan-cancer analysis of whole genomes. Nature. 2020; 578(7793): 82–93.
[3] Rady I, Mohamed H, Rady M, Siddiqui IA, Mukhtar H. Cancer preventive and therapeutic effects of EGCG, the major polyphenol in green tea. Egypt J Basic Appl Sci. 2018; 5(1): 1–23.
[4] Johnson LA, June CH. Driving gene-engineered T cell immunotherapy of cancer.Cell Res. 2017; 27(1): 38–58.
[5] Muhamad N, Plengsuriyakarn T, Na-Bangchang K. Application of active targeting nanoparticle delivery system for chemotherapeutic drugs and traditional/herbal medicines in cancer therapy: a systematic review. Int J Nanomed. 2018; 13: 3921–3935.
[6] Rostami-Nejad M, Razzaghi M, Esmaeili S, Zali A, Rezaei-Tavirani M, Heidari MH, Rezaei-Tavirani M, Zamanian-Azodi M, Ahmadi N. Evaluation of anticancer and neuroprotective properties of curcumin: a network analysis. Res J Pharmacogn. 2020; 7(3): 85–92.
[7] Xiao Z, Morris‐Natschke SL, Lee KH. Strategies for the optimization of natural leads to anticancer drugs or drug candidates. Med Res Rev. 2016; 36(1): 32–91.
[8] Kamaruddin MF, Hossain MZ, Mohamed Alabsi A, Mohd Bakri M. The antiproliferative and apoptotic effects of capsaicin on an oral squamous cancer cell line of Asian origin, ORL-48. Medicina. 2019; 55(7): 1–12.
[9] Dalilan S, Rezaei-Tavirani M, Nabiuni M, Heidari-Keshel S, Azodi MZ, Zali H. Aqueous extract of Lavender angustifolia inhibits lymphocytes proliferation of hodgkin's lymphoma patients. Iran J Cancer Prev. 2013; 6(4): 201–208.
[10] Roodsari MR, Zamanian-Azodi M, Salimpour F. Herbal remedies and medicine; introducing some Iranian plants. J Paramed Sci. 2013; 4(2): 116-122.
[11] Khatib H, Rezaei-Tavirani M, Keshel SH, Azodi MZ, Omidi R, Biglarian M, Sobhi S. Flow cytometry analysis of Rosa damascena effects on gastric cancer cell line (MKN45).Iran J Cancer Prev. 2013; 6(S): 30-36.
[12] Yang CS, Wang X. Green tea and cancer prevention. Nutr Cancer. 2010; 62(7): 931–937.
[13] Wang Y, Zhao Y, Chong F, Song M, Sun Q, Li T, Xu L, Song C. A dose-response meta-analysis of green tea consumption and breast cancer risk. Int J Food Sci Nutr. 2020: 71(6): 656–667.
[14] Henning SM, Wang P, Lee R-P, Trang A, Husari G, Yang J, Grojean EM, Ly A, Hsu M, Heber D, Grogan T, Li Z, Aronson WJ. Prospective randomized trial evaluating blood and prostate tissue concentrations of green tea polyphenols and quercetin in men with prostate cancer. Food Funct. 2020; 11(5): 4114–4122.
[15] Yi Y, Liang H, Jing H, Jian Z, Guang Y, Jun Z, Zhu H, Jian L. Green tea consumption and esophageal cancer risk: a meta-analysis. Nutr Cancer. 2020; 72(3): 513–521.
[16] Ramshankar V, Krishnamurthy A. Chemoprevention of oral cancer: green tea experience. J Nat Sci Biol Med. 2014; 5(1): 3–7.
[17] Cabrera C, Artacho R, Giménez R. Beneficial effects of green tea-a review. J Am Coll Nutr. 2006; 25(2): 79–99.
[18] Weinreb O, Mandel S, Amit T, Youdim MB. Neurological mechanisms of green tea polyphenols in Alzheimer's and Parkinson's diseases.J Nutr Biochem. 2004; 15(9): 506–516.
[19] Imai K, Nakachi K. Cross sectional study of effects of drinking green tea on cardiovascular and liver diseases. Br Med J. 1995; 310(6981): 693–696.
[20] Abe SK, Inoue M. Green tea and cancer and cardiometabolic diseases: a review of the current epidemiological evidence.
Eur J Clin Nutr. In press.
[21] Lu QY, Yang Y, Jin YS, Zhang ZF, Heber D, Li FP, Dubinett SM, Sondej MA, Loo JA, Rao JY. Effects of green tea extract on lung cancer A549 cells: proteomic identification of proteins associated with cell migration. Proteomics. 2009; 9(3): 757–767.
[22] Fuchs-Tarlovsky V. Role of antioxidants in cancer therapy. Nutrition. 2013; 29(1): 15-21.
[23] Miyata Y, Shida Y, Hakariya T, Sakai H. Anti-cancer effects of green tea polyphenols against prostate cancer. Molecules. 2019; 24(1): 1–19.
[24] Chen BH, Hsieh CH, Tsai SY, Wang CY, Wang CC. Anticancer effects of epigallocatechin-3-gallate nanoemulsion on lung cancer cells through the activation of AMP-activated protein kinase signaling pathway. Sci Rep. 2020; 10(1): 1–11.
[25] Wei R, Wirkus J, Yang Z, Machuca J, Esparza Y, Mackenzie GG. EGCG sensitizes chemotherapeutic-induced cytotoxicity by targeting the ERK pathway in multiple cancer cell lines. Arch Biochem Biophys. 2020; Article ID 108546.
[26] Ahmed RSI, Soave C, Edbauer TG, Patel KR, Elghoul Y, de Oliveira AVP, Renzetti A, Foldes R, Chan TH, Dou QP. Discovery of green tea polyphenol-based antitumor drugs: mechanisms of action and clinical implications.  In: Joshee N, Dhekney S, Parajuli P Eds. Medicinal Plants. Springer, 2019
[27] Zhang L, Chen W, Tu G, Chen X, Lu Y, Wu L, Zheng Dl. Enhanced chemotherapeutic efficacy of PLGA-encapsulated epigallocatechin gallate (EGCG) against human lung cancer. Int J Nanomed. 2020; 15: 4417–4429.
[28] Rezaei-Tavirani M, Rezaei-Tavirani M, Zamanian Azodi M. Investigating therapeutic effects of retinoic acid on thyroid cancer via protein-protein interaction network analysis. Int J Cancer Manag. 2019; 12(10): 1–8.
[29] Zamanian Azodi M, Rezaei-Tavirani M, Rezaei Tavirani M. Investigating the effects of ibuprofen on the gene expression profile in hippocampus of mice model of Alzheimer’s disease through bioinformatics analysis. Iran J Pharm Res. 2020; 19(2): 352–359.
[30] Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003; 13(11): 2498–2504.
[31] Assenov Y, Ramírez F, Schelhorn SE, Lengauer T, Albrecht M. Computing topological parameters of biological networks. Bioinformatics. 2008; 24(2): 282–284.
[32] Li BQ, Huang T, Liu L, Cai YD, Chou KC. Identification of colorectal cancer related genes with mRMR and shortest path in protein-protein interaction network. PlosOne. 2012; 7(4): 1–12.
[33] Azodi MZ, Arjmand B, Zali A, Razzaghi M. Introducing APOA1 as a key protein in COVID-19 Infection: a bioinformatics approach. Gastroenterol Hepatol Bed Bench. 2020; 13(4): 367–373.
[34] Bindea G, Mlecnik B, Hackl H, Charoentong P, Tosolini M, Kirilovsky A, Fridman WF, Pagès F, Trajanoski Z, Galon J. ClueGO: a cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009; 25(8): 1091–1093.
[35] Bindea G, Galon J, Mlecnik B. CluePedia cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics. 2013; 29(5): 661–663.
[36] Choi YD, Grabowski PJ, Sharp PA, Dreyfuss G. Heterogeneous nuclear ribonucleoproteins: role in RNA splicing. Science. 1986; 231(4745): 1534-1539.
[37] Han N, Li W, Zhang M. The function of the RNA-binding protein hnRNP in cancer metastasis. J Cancer Res Ther. 2013; 9(7): 129–134.
[38] Carpenter B, MacKay C, Alnabulsi A, MacKay M, Telfer C, Melvin WT, Murray GI. The roles of heterogeneous nuclear ribonucleoproteins in tumour development and progression. Biochim Biophys Acta Rev Cancer. 2006; 1765(2): 85–100.
[39] Lu Y, Yao R, Yan Y, Wang Y, Hara Y, Lubet RA, You M. A gene expression signature that can predict green tea exposure and chemopreventive efficacy of lung cancer in mice. Cancer Res. 2006; 66(4): 1956–1963.
[40] Ding X, Du J, Zhang K, Bai S, Zeng Q, Peng H, Xuan Y, Su Z, Wang J. Tandem mass tag-based quantitative proteomics analysis and gelling properties in egg albumen of laying hens feeding tea polyphenols. Poult Sci. 2020; 99(1): 430–440.
[41] Dowling P, Pollard D, Larkin A, Henry M, Meleady P, Gately K, O'Byrne K, Barr MP, Lynch V, Ballot J, Crown J, Moriarty M, O'Brien E, Morgan R, Clynes M. Abnormal levels of heterogeneous nuclear ribonucleoprotein A2B1 (hnRNPA2B1) in tumour tissue and blood samples from patients diagnosed with lung cancer. Mol Biosyst. 2015; 11(3): 743–752.
[42] Salviano-Silva A, Lobo-Alves SC, Almeida RCd, Malheiros D, Petzl-Erler ML. Besides pathology: long non-coding RNA in cell and tissue homeostasis. Non-coding RNA. 2018; 4(1): 1–30.
[43] Liu Y, Gai L, Liu J, Cui Y, Zhang Y, Feng J. Expression of poly (C)-binding protein 1 (PCBP1) in NSCLC as a negative regulator of EMT and its clinical value. Int J Clin Exp Pathol. 2015; 8(6): 7165–7172.
[44] Shi H, Li H, Yuan R, Guan W, Zhang X, Zhang S, Zhang W, Tong F, Li L, Song Z, Wang C, Yang S, Wang H. PCBP1 depletion promotes tumorigenesis through attenuation of p27 Kip1 mRNA stability and translation. J Exp Clin Cancer Res. 2018; 37(1): 1–18.
[45] Geuens T, De Winter V, Rajan N, Achsel T, Mateiu L, Almeida-Souza L, Asselbergh B, Bouhy D, Auer-Grumbach M, Bagni C, Timmerman V. Mutant HSPB1 causes loss of translational repression by binding to PCBP1, an RNA binding protein with a possible role in neurodegenerative disease. Acta Neuropathol Commun. 2017; 5(1): 1–15.
[46] Ko CC, Chen YJ, Chen CT, Liu YC, Cheng FC, Hsu KC, Chow LP. Chemical proteomics identifies heterogeneous nuclear ribonucleoprotein (hnRNP) A1 as the molecular target of quercetin in its anti-cancer effects in PC-3 cells. J Biol Chem. 2014; 289(32): 22078–22089.
[47] Herdy B, Karonitsch T, Vladimer GI, Tan CS, Stukalov A, Trefzer C, Bigenzahn JW, Theil T, Holinka J, Kiener HP, Colinge J, Bennett KL, Superti-Furga G. The RNA‐binding protein HuR/ELAVL1 regulates IFN‐β mRNA abundance and the type I IFN response. Eur J Immunol. 2015; 45(5): 1500–1511.
[48] Xue F, Li QR, Xu YH, Zhou HB. MicroRNA-139-3p inhibits the growth and metastasis of ovarian cancer by inhibiting ELAVL1. OncoTargets Ther. 2019; 12: 8935–8945.
[49] Wang M, Mao C, Ouyang L, Liu Y, Lai W, Liu N, Shi Y, Chen L, Xiao D, Yu F, Wang X, Zhou H, Cao Y, Liu S, Yan Q, Tao Y, Zhang B. Long noncoding RNA LINC00336 inhibits ferroptosis in lung cancer by functioning as a competing endogenous RNA. Cell Death Differ. 2019; 26(11): 2329–2343.
[50] Matsuo T, Miyata Y, Asai A, Sagara Y, Furusato B, Fukuoka J, Sakai H. Green tea polyphenol induces changes in cancer-related factors in an animal model of bladder cancer. PlosOne. 2017; Article ID e0171091.
[51] Melling N, Taskin B, Hube‐Magg C, Kluth M, Minner S, Koop C, Grob T, Graefen M, Heinzer H, Tsourlakis MC, Izbicki J, Wittmer C, Huland H, Simon R, Wilczak W, Sauter G, Steurer S, Schlomm T, Krech T. Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate. 2016; 76(3): 259–272.
[52] Gu C, Zhang M, Sun W, Dong C. Upregulation of miR-324-5p inhibits proliferation and invasion of colorectal cancer cells by targeting ELAVL1. Oncology Res. 2019; 27(5): 515–524.
[53] Cao H, Kelly MA, Kari F, Dawson HD, Urban JF, Coves S, Roussel AM, Anderson RA. Green tea increases anti-inflammatory tristetraprolin and decreases pro-inflammatory tumor necrosis factor mRNA levels in rats. J Inflamm. 2007; 4: 1–12.
[54] Maiti S, Nazmeen A, Medda N, Patra R, Ghosh TK. Flavonoids green tea against oxidant stress and inflammation with related human diseases. Clin Nutr Exp. 2019; 24: 1–14.